arrow
D

David J. Straus

Memorial Sloan Kettering Cancer Center
H指数:58
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

自体干细胞移植后,外周T细胞淋巴瘤的罗米地辛维持治疗

2025-04-070
OAAI
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation (vol 109, pg 1149, 2024)

免疫化学疗法联合来那度胺治疗高危套细胞淋巴瘤,并进行可测量的残留疾病评估 (109卷,1149页,2024页)

2024-08-010
OAAI
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
2024-04-280
OAAI
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
2023-08-312
OAAI
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
2023-08-312
OAAI
Retrospective characterization of nodal marginal zone lymphoma
2023-08-244
OAAI
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

Brentuximab Vedotin在III期或IV期霍奇金淋巴瘤中的总体生存率

2022-07-28158
OA
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
2022-07-198
OA
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
2022-02-102
OAAI
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
2021-07-2922
OAAI
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
2021-06-1644
OAAI
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin联合化疗治疗III期或IV期经典霍奇金淋巴瘤 (ECHELON-1): 一项国际、开放标签、随机、3期试验的5年更新

2021-06-0198
PRE
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
2020-10-0172
OAAI
Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas
2020-08-150
PRE
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
2020-07-2812
OAAI
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
2020-07-17114
OAAI